Q1 2022 sales growth of 8.6% at CER driven by Dupixent and CHC. Specialty Care grew 17.8% driven by Dupixent (€1,614 million, +45.7%). Vaccines were up 6.8% reflecting strong PPH franchise as well as gradual recovery of Travel vaccines. General Medicines core assets up 4.7% driven by Rezurock® and overall GBU sales broadly stable (-0.7%). CHC continued strong growth momentum (+17.0%) driven by Cough & Cold and Pain care categories. Q1 2022 business EPS up 16.1% at CER driven by higher sales and improving margins

BOI margin reached 31.7% up 1.0 ppt reflecting improvement in gross margin while investing in R&D.

Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate

Progress on Corporate Social Responsibility strategy

Sanofi continues its progress to improve access to medicines; issuing a sustainability-linked bond and publishing its global access and pricing policy. Sanofi is working with experts from leading oncology institutions to reach its CSR ambitions on childhood cancer

Key milestone and regulatory achievements on R&D transformation

Efanesoctocog alfa met phase 3 primary endpoint in hemophilia A and demonstrated superiority to prior factor prophylaxis

Dupixent approved in EU for severe asthma in children aged 6 to 11 years; Priority Review obtained in atopic dermatitis for children (6 months to 5 years) and eosinophilic esophagitis patients 12 years and older in the U.S.

Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants

FDA approved Enjaymo, first treatment for use in patients with cold agglutinin disease (CAD)

Xenpozyme approved in Japan, the first and only approved therapy indicated to treat acid sphingomyelinase deficiency (ASMD).

Sanofi and GSK applied for conditional regulatory authorization for their first-generation Covid-19 vaccine in Europe with data supporting its use as a universal booster, designed to boost all currently approved COVID-19 vaccine platforms

2022 financial outlook

Sanofi expects 2022 business EPS to grow low double-digit at CER, barring unforeseen major adverse events. Applying average April 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated to be between +4% to +5%

Sanofi Chief Executive Officer, Paul Hudson, commented: “We are off to a strong start to 2022 propelled by the continued outstanding performance of Dupixent, double-digit growth of our CHC business and improved margins in the first quarter. In R&D, we increased our investments to fuel our rapidly advancing pipeline which was further enhanced through BD collaborations such as Seagen, IGM, Exscientia and Blackstone during the period. As highlighted at our investor event in March, we remain focused on our path to industry leadership in Immunology with a broad set of novel treatments in development, including additional indications for Dupixent in diseases such as Prurigo Nodularis and Eosinophilic Esophagitis which were recently submitted for regulatory approval. In addition, we are particularly excited about the positive pivotal trial readout for efanesoctogog alfa, our potentially revolutionizing treatment for Hemophilia A patients, with its filing planned for mid-year. Also in the quarter, we continued to execute well against our strategic priorities with our decision for the proposed EUROAPI shares listing and spin-off through an extraordinary dividend. Based on the strong first quarter, we are on track to deliver on our 2022 financial guidance, despite the challenging business environment.“